United States Pharmaceuticals

Apellis Pharmaceuticals Inc (APLS)

Track

The most recent insider trading activity at Apellis Pharmaceuticals occurred on February 11, 2026, involving a sale by an officer. Prior to this, a series of sales were executed by multiple executives on January 22, 2026. All recorded transactions in the provided data consist of sales or proposed sales by company insiders.
Ticker: APLS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Apellis Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 11 Feb 2026
Value US$2,112,541.11 | Price 449.09 | Shares 34,469 (+22.7%)
Proposed sale 11 Feb 2026
Value US$846,675.95 | Price 103.76 | Shares 82,637
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-13 2026-02-11 S Sale
3.7
DeLong Mark Jeffrey

Chief Business & Strat Officer

Officer
34,469 +22.7%
449.09
US$2,112,541 		34,469 +22.7% 449.09 US$2,112,541
2026-02-11 2026-02-11 PrS Proposed sale
3.7
DeLong Mark Jeffrey

Officer

Officer
82,637
103.76
US$846,676 		82,637 103.76 US$846,676
2026-01-23 2026-01-22 S Sale
4.1
Deschatelets Pascal

Chief Scientific Officer

Officer
98,173 +13.6%
329.34
US$3,820,180 		98,173 +13.6% 329.34 US$3,820,180
2026-01-23 2026-01-22 S Sale
3.7
DeLong Mark Jeffrey

Chief Business & Strat Officer

Officer
3,371 -4.1%
21.77
US$73,371 		3,371 -4.1% 21.77 US$73,371
2026-01-23 2026-01-22 S Sale
3.6
Chopas James George

VP/Chief Accounting Officer

Officer
2,064 -4.0%
21.77
US$44,924 		2,064 -4.0% 21.77 US$44,924
2026-01-23 2026-01-22 S Sale
2.9
Baumal Caroline

Chief Medical Officer

Officer
2,797 -3.1%
21.77
US$60,878 		2,797 -3.1% 21.77 US$60,878
2026-01-23 2026-01-22 S Sale
3.4
Watson David O.

General Counsel

Officer
7,832 -8.1%
21.77
US$170,467 		7,832 -8.1% 21.77 US$170,467
2026-01-23 2026-01-22 S Sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
10,287 -9.9%
21.77
US$223,901 		10,287 -9.9% 21.77 US$223,901
2026-01-23 2026-01-22 S Sale
4.0
Francois Cedric

Chief Executive Officer

Executive Director
27,192 -8.7%
21.77
US$591,845 		27,192 -8.7% 21.77 US$591,845
2026-01-23 2026-01-22 S Sale
3.1
Nicholson Nur

Chief Technical Officer

Officer
7,725 -9.8%
21.77
US$168,138 		7,725 -9.8% 21.77 US$168,138
2026-01-22 2026-01-22 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
7,832
21.77
US$170,467 		7,832 21.77 US$170,467
2026-01-22 2026-01-22 PrS Proposed sale
4.1
Deschatelets Pascal

Officer

Officer
5,928
21.77
US$129,025 		5,928 21.77 US$129,025
2026-01-22 2026-01-22 PrS Proposed sale
3.4
Sullivan Timothy Eugene

Officer

Officer
10,287
21.77
US$223,901 		10,287 21.77 US$223,901
2026-01-22 2026-01-22 PrS Proposed sale
3.7
DeLong Mark Jeffrey

Officer

Officer
3,371
21.77
US$73,371 		3,371 21.77 US$73,371
2026-01-22 2026-01-22 PrS Proposed sale
4.0
Francois Cedric

Officer

Officer
27,192
21.77
US$591,845 		27,192 21.77 US$591,845
2026-01-22 2026-01-22 PrS Proposed sale
3.1
Nicholson Nur

Officer

Officer
7,725
21.77
US$168,138 		7,725 21.77 US$168,138
2026-01-22 2026-01-22 PrS Proposed sale
3.6
Chopas James George

Officer

Officer
2,064
21.77
US$44,924 		2,064 21.77 US$44,924
2026-01-22 2026-01-22 PrS Proposed sale
2.9
Baumal Caroline

Officer

Officer
2,797
21.77
US$60,878 		2,797 21.77 US$60,878
2026-01-21 2026-01-20 S Sale
4.0
Francois Cedric

Chief Executive Officer

Executive Director
8,182 -2.5%
19.79
US$161,946 		8,182 -2.5% 19.79 US$161,946
2026-01-21 2026-01-20 S Sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
2,892 -2.7%
19.79
US$57,241 		2,892 -2.7% 19.79 US$57,241
2026-01-21 2026-01-20 S Sale
4.1
Deschatelets Pascal

Chief Scientific Officer

Officer
909 -0.1%
19.79
US$17,992 		909 -0.1% 19.79 US$17,992
2026-01-21 2026-01-20 S Sale
3.1
Nicholson Nur

Chief Technical Officer

Officer
2,203 -2.7%
19.79
US$43,604 		2,203 -2.7% 19.79 US$43,604
2026-01-21 2026-01-20 S Sale
3.6
Chopas James George

VP/Chief Accounting Officer

Officer
726 -1.4%
19.79
US$14,370 		726 -1.4% 19.79 US$14,370
2026-01-21 2026-01-20 S Sale
3.7
DeLong Mark Jeffrey

Chief Business & Strat Officer

Officer
1,334 -1.6%
19.79
US$26,404 		1,334 -1.6% 19.79 US$26,404
2026-01-21 2026-01-20 S Sale
2.9
Baumal Caroline

Chief Medical Officer

Officer
1,882 -2.1%
19.79
US$37,250 		1,882 -2.1% 19.79 US$37,250
2026-01-21 2026-01-20 S Sale
3.4
Watson David O.

General Counsel

Officer
2,475 -2.5%
19.79
US$48,987 		2,475 -2.5% 19.79 US$48,987
2026-01-20 2026-01-20 PrS Proposed sale
3.1
Nicholson Nur

Officer

Officer
2,203
19.79
US$43,604 		2,203 19.79 US$43,604
2026-01-20 2026-01-20 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
2,475
19.79
US$48,987 		2,475 19.79 US$48,987
2026-01-20 2026-01-20 PrS Proposed sale
4.0
Francois Cedric

Officer

Officer
8,182
19.79
US$161,946 		8,182 19.79 US$161,946
2026-01-20 2026-01-20 PrS Proposed sale
3.7
DeLong Mark Jeffrey

Officer

Officer
1,334
19.79
US$26,404 		1,334 19.79 US$26,404
2026-01-20 2026-01-20 PrS Proposed sale
4.1
Deschatelets Pascal

Officer

Officer
909
19.79
US$17,992 		909 19.79 US$17,992
2026-01-20 2026-01-20 PrS Proposed sale
2.9
Baumal Caroline

Officer

Officer
1,882
19.79
US$37,250 		1,882 19.79 US$37,250
2026-01-20 2026-01-20 PrS Proposed sale
3.4
Sullivan Timothy Eugene

Officer

Officer
2,892
19.79
US$57,241 		2,892 19.79 US$57,241
2026-01-20 2026-01-20 PrS Proposed sale
3.6
Chopas James George

Officer

Officer
726
19.79
US$14,370 		726 19.79 US$14,370
2026-01-15 2026-01-13 S Sale
3.1
Nicholson Nur

Chief Technical Officer

Officer
2,618 -3.1%
22.19
US$58,086 		2,618 -3.1% 22.19 US$58,086
2026-01-15 2026-01-13 S Sale
3.6
Chopas James George

VP/Chief Accounting Officer

Officer
873 -1.6%
22.19
US$19,369 		873 -1.6% 22.19 US$19,369
2026-01-15 2026-01-13 S Sale
3.7
DeLong Mark Jeffrey

Chief Business & Strat Officer

Officer
1,780 -2.1%
22.19
US$39,493 		1,780 -2.1% 22.19 US$39,493
2026-01-15 2026-01-13 S Sale
4.0
Francois Cedric

Chief Executive Officer

Executive Director
10,186 -3.1%
22.19
US$225,999 		10,186 -3.1% 22.19 US$225,999
2026-01-15 2026-01-13 S Sale
4.1
Deschatelets Pascal

Chief Scientific Officer

Officer
2,277 -0.2%
22.19
US$50,520 		2,277 -0.2% 22.19 US$50,520
2026-01-15 2026-01-13 S Sale
3.4
Watson David O.

General Counsel

Officer
5,780 -5.5%
22.19
US$128,242 		5,780 -5.5% 22.19 US$128,242
2026-01-15 2026-01-13 S Sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
3,856 -3.5%
22.19
US$85,554 		3,856 -3.5% 22.19 US$85,554
2026-01-13 2026-01-13 PrS Proposed sale
3.1
Nicholson Nur

Officer

Officer
2,618
22.19
US$58,086 		2,618 22.19 US$58,086
2026-01-13 2026-01-13 PrS Proposed sale
3.6
Chopas James George

Officer

Officer
873
22.19
US$19,369 		873 22.19 US$19,369
2026-01-13 2026-01-13 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
5,780
22.19
US$128,242 		5,780 22.19 US$128,242
2026-01-13 2026-01-13 PrS Proposed sale
3.7
DeLong Mark Jeffrey

Officer

Officer
1,780
22.19
US$39,493 		1,780 22.19 US$39,493
2026-01-13 2026-01-13 PrS Proposed sale
4.1
Deschatelets Pascal

Officer

Officer
2,277
22.19
US$50,520 		2,277 22.19 US$50,520
2026-01-13 2026-01-13 PrS Proposed sale
4.0
Francois Cedric

Officer; Director

Executive Director
10,186
22.19
US$225,999 		10,186 22.19 US$225,999
2026-01-13 2026-01-13 PrS Proposed sale
3.4
Sullivan Timothy Eugene

Officer

Officer
3,856
22.19
US$85,554 		3,856 22.19 US$85,554
2026-01-06 2026-01-05 S Sale
2.9
Baumal Caroline

Chief Medical Officer

Officer
3,020 -3.2%
25.53
US$77,097 		3,020 -3.2% 25.53 US$77,097
2026-01-05 2026-01-05 PrS Proposed sale
2.9
Baumal Caroline

Officer

Officer
3,020
25.53
US$77,097 		3,020 25.53 US$77,097
2025-12-18 2025-12-16 PlS Planned sale
3.4
Watson David O.

General Counsel

Officer
5,000 -4.6%
24.49
US$122,450 		5,000 -4.6% 24.49 US$122,450
2025-12-16 2025-12-16 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
5,000
24.49
US$122,450 		5,000 24.49 US$122,450
2025-11-18 2025-11-17 PlS Planned sale
3.4
Watson David O.

General Counsel

Officer
5,000 -4.4%
20.06
US$100,300 		5,000 -4.4% 20.06 US$100,300
2025-11-17 2025-11-17 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
5,000
20.06
US$100,300 		5,000 20.06 US$100,300
2025-10-23 2025-10-21 PlS Planned sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
10,000 -8.3%
28.03
US$280,300 		10,000 -8.3% 28.03 US$280,300
2025-10-21 2025-10-21 PrS Proposed sale
3.4
Sullivan Timothy Eugene

Officer

Officer
10,000
28.03
US$280,300 		10,000 28.03 US$280,300
2025-10-17 2025-10-16 PlS Planned sale
3.4
Watson David O.

General Counsel

Officer
5,000 -4.2%
25.22
US$126,100 		5,000 -4.2% 25.22 US$126,100
2025-10-16 2025-10-16 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
5,000
25.22
US$126,100 		5,000 25.22 US$126,100
2025-10-15 2025-10-10 PlS Planned sale
3.1
Dunlop A. Sinclair
Non-Executive Director
31,092 -89.0%
23.72
US$737,536 		31,092 -89.0% 23.72 US$737,536
2025-10-02 2025-09-30 PlS Planned sale
3.1
Dunlop A. Sinclair
Non-Executive Director
31,092 -47.8%
22.58
US$702,057 		31,092 -47.8% 22.58 US$702,057
2025-09-19 2025-09-19 PrS Proposed sale
3.1
Dunlop A. Sinclair

Director

Non-Executive Director
93,276
22.95
US$2,140,917 		93,276 22.95 US$2,140,917
2025-09-19 2025-09-19 PlS Planned sale
3.1
Dunlop A. Sinclair
Non-Executive Director
31,092 -31.1%
22.95
US$713,561 		31,092 -31.1% 22.95 US$713,561
2025-09-18 2025-09-16 PlS Planned sale
3.4
Watson David O.

General Counsel

Officer
5,000 -4.0%
24.34
US$121,700 		5,000 -4.0% 24.34 US$121,700
2025-09-16 2025-09-16 PrS Proposed sale
3.4
Watson David O.

Officer

Officer
5,000
24.34
US$121,700 		5,000 24.34 US$121,700
2025-09-17 2025-09-15 S Sale
3.6
Chopas James George

VP/Chief Accounting Officer

Officer
189 -0.4%
24.19
US$4,572 		189 -0.4% 24.19 US$4,572
2025-09-15 2025-09-15 PrS Proposed sale
3.6
Chopas James George

Officer

Officer
189
24.19
US$4,572 		189 24.19 US$4,572
2025-09-12 2025-09-10 S Sale
3.4
Watson David O.

General Counsel

Officer
20,000 -28.5%
26.17
US$523,400 		20,000 -28.5% 26.17 US$523,400
2025-09-10 2025-09-10 PrS Proposed sale
3.4
THE DAVID O WATSON IRREV TR OF 2023

Officer

Officer
20,000
26.17
US$523,436 		20,000 26.17 US$523,436
2025-09-10 2025-09-08 S Sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
10,000 -14.2%
27.83
US$278,300 		10,000 -14.2% 27.83 US$278,300
2025-09-10 2025-09-08 PlS Planned sale
3.4
Sullivan Timothy Eugene

Chief Financial Officer

Officer
32,729 -22.8%
27.86
US$911,830 		32,729 -22.8% 27.86 US$911,830
2025-09-08 2025-09-08 PrS Proposed sale
3.4
Timothy E Sullivan Irrevocable Trust of 2023 DTD 03/30/2023

Officer

Officer
10,000
28.00
US$280,000 		10,000 28.00 US$280,000
2025-09-08 2025-09-08 PrS Proposed sale
3.4
Sullivan Timothy Eugene

Officer

Officer
32,729
27.86
US$911,830 		32,729 27.86 US$911,830
2025-09-03 2025-09-02 S Sale
3.6
Chopas James George

VP/Chief Accounting Officer

Officer
548 -1.0%
28.08
US$15,386 		548 -1.0% 28.08 US$15,386
2025-09-02 2025-09-02 PrS Proposed sale
3.6
Chopas James George

Officer

Officer
548
28.08
US$15,386 		548 28.08 US$15,386
2025-08-29 2025-08-28 S Sale
4.0
Francois Cedric

Chief Executive Officer

Executive Director
49,963 -14.0%
28.39
US$1,418,450 		49,963 -14.0% 28.39 US$1,418,450
Explore more

More insider trading research around Apellis Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America